SavedAdd your journal

Journals / MN Kardiyoloji / 2006 / Cilt: 13 - Sayı: 2

A frequently overlooked condition in patients taking spironolactone in addition to angiotensin converting enzyme inhibitors or angiotensin receptor blockers: hyperkalemia (Case report)

Anjiotensin konverting enzim inhibitörleri veya anjiotensin reseptör blokerlerine ilave olarak spironolakton kullanan hastalarda gözden kaçan bir ayrıntı: Hiperkalemi (Olgu sunumu)

Nihal AKAR
Murat SAKALLI
Tuğba KAYHAN
ALPER CANBAY
Erdem DİKER
Sinan AYDOĞDU
Pages
129–132
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herewith, we presented two patients who experienced severe hyperkalemia during treatment both angiotensin converting enzyme inhibitors or angiotensin reseptor blockade and spironolactone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Use of spironolactone in the maintanence therapy of severe congestive heart failure or refractory hypertension, became widespread after being awared that of beneficial effects of sprinolactone on mortality and morbidity in these patient subset.
📊
Key Findings & Data:Some sporadic cases of hyperkalemia due to spironolactone therapy in these patients were reported in the past.
💡
Conclusion & Impact:Herewith, we presented two patients who experienced severe hyperkalemia during treatment both angiotensin converting enzyme inhibitors or angiotensin reseptor blockade and spironolactone.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anjiyotensin II tip1 reseptör blokerleri · Spironolakton · Anjiyotensin dönüştürücü enzim inhibitörleri

Abstract

Use of spironolactone in the maintanence therapy of severe congestive heart failure or refractory hypertension, became widespread after being awared that of beneficial effects of sprinolactone on mortality and morbidity in these patient subset. Some sporadic cases of hyperkalemia due to spironolactone therapy in these patients were reported in the past. Herewith, we presented two patients who experienced severe hyperkalemia during treatment both angiotensin converting enzyme inhibitors or angiotensin reseptor blockade and spironolactone.

Özet

Ciddi konjestif kalp yetmezliği veya refrakter hipertansiyonu olan hastalarda standart tedaviye spironolakton eklenmesinin mortalite ve morbidite üzerindeki olumlu etkileri görüldükten sonra spironolakton kullanımı yaygınlaşmıştır. Literatürde bu kombine tedaviye bağlı hiperkalemi vakaları bildirilmiştir. Bu yazıda anjiotensin konverting enzim inhibitörü veya anjiotensin reseptör blokeri ile birlikte spironolakton kullanımına bağlı hiperkalemi gelişen iki olgu sunulmuştur.

🔖

Cite This Article

AKAR, N., SAKALLI, M., KAYHAN, T., CANBAY, A., DİKER, E., AYDOĞDU, S. (2006). A frequently overlooked condition in patients taking spironolactone in addition to angiotensin converting enzyme inhibitors or angiotensin receptor blockers: hyperkalemia (Case report). MN Kardiyoloji, Cilt: 13 - Sayı: 2, 129–132. https://ajindex.com/articles/297535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Miller AB, Srivastava P. Angiotensin receptor blockers and aldosterone antogonists in chronic heart failure. Cardiol Clin 2001; 19:195-202. McMahon EG. Recent studies with eplerenone, a novel se­ lective aldosterone antogonist. Curr Opin Pharmacol 2001; 1:190-6.
  2. McKelvie RS, Yusuf S, Pericak D. and et al. Comparison of candesartan, enalapril and their combination in congestive heart failure. Circulation 1999; 100:1056-64.
  3. Staessen J, Lijnen P, Fagard R. and et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91:457-65.
  4. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-30.
  5. Messerli FH, Grossman E, Goldbourt U. Are beta-blocers efficacious as first-line therapy for hyperyension in the elderly? JAMA 1998; 279:1903-7. The ALLHAT officers and Coordinators fort he ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-97. Laragh J: Laragh's lessons for treating hypertension. Am J Hypertens 2001; 14:84-9.
  6. Ouzan J, Perault C, Lincoff M. and et al. Te role of spirono­ lactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-9.
  7. Nishizaka MK, Zaman MA, Calhoun Da. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-30.
  8. Flack JM, Oparil S, Pratt JH. and et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41:1148-55.
  9. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threating hyperkalemia during combined therapy with angioten­sin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438-41.
  10. Wrenger E, Müler R, Moesenthin M, Welte T, Frölich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors of 44 cases. BMJ; 2003: 327:147-50.
  11. Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J. Hyperkalemia in the elderly. Clin Chem 1984; 30:1409-12. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting-enzyme inhibitor and loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 199